We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Baseline in vitro Activity of Tigecycline among Key Bacterial Pathogens Exhibiting Multidrug Resistance.
- Authors
Draghi, Deborah C.; Tench, Stacy; Dowzicky, Michael J.; Sahm, Daniel F.
- Abstract
Tigecycline is the first clinically available semisynthetic glycylcycline approved for clinical use. This study was done to establish a baseline for ongoing surveillance of tigecycline’s activity as this agent’s clinical use increases. Against 1,796 Staphylococcus aureus (559 multidrug resistant), tigecycline had the lowest minimal inhibitory concentration (MIC90; 0.12 μg/ml) among all agents tested and 99.8% of the isolates were susceptible. For Acinetobacter spp., tigecycline again demonstrated the lowest MIC90 (2 μg/ml) and the highest percent susceptibility (96.9%). Among Enterobacteriaceae, the 2 most active agents were tigecycline (MIC90 = 1 μg/ml; 99% susceptible) and imipenem (MIC90 = 1 μg/ml; 99.5% susceptible). Tigecycline also demonstrated high activity against Streptococcus pneumoniae, Streptococcus pyogenes,Haemophilus influenzae and Enterococcus spp. In summary, tigecycline currently exhibits potent activity against a broad array of bacteria species. Given the dynamics of resistance development, careful monitoring of tigecycline activity against these organisms should remain a significant aspect of ongoing surveillance. Copyright © 2008 S. Karger AG, Basel
- Subjects
ACINETOBACTER; STAPHYLOCOCCUS aureus; ENTEROBACTERIACEAE; HAEMOPHILUS influenzae; ENTEROCOCCUS
- Publication
Chemotherapy (0009-3157), 2008, Vol 54, Issue 2, p91
- ISSN
0009-3157
- Publication type
Article
- DOI
10.1159/000118660